The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells

Molecules and Cells

Volumn 37, Issue 11, 2014, Pages 812-818

  Wang, Hui ^a   Lu, Changqing ^a   Li, Qing ^a   Xie, Jun ^a   Chen, Tongbing ^a   Tan, Yan ^a   Wu, Changping ^a   Jiang, Jingting ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Doxorubicin; Kif4A; MCF 7; MDA MB 231; PARP 1

Indexed keywords

3 AMINOBENZAMIDE; ALPHA TUBULIN; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN; PROTEIN KIF4A; PROTEIN P53; UNCLASSIFIED DRUG; 3-AMINOBENZAMIDE; ANTINEOPLASTIC ANTIBIOTIC; BENZAMIDE DERIVATIVE; KIF4A PROTEIN, HUMAN; KINESIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINESIN; MCF-7 CELLS; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84964313942     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.0210     Document Type: Article

References (27)

1. Alli, E., Sharma, V.B., Hartman, A.R., Lin, P.S., McPherson, L., and Ford, J.M. (2011). Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 11, 7.
2. Annunziata, C.M., and Bates, S.E. (2010). PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol. Rep. 2.
3. Borysov, S.I., Granic, A., Padmanabhan, J., Walczak, C.E., and Potter, H. (2011). Alzheimer Abeta disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. Cell Cycle 10, 1397-1410.
4. Campalans, A., Kortulewski, T., Amouroux, R., Menoni, H., Vermeulen, W., and Radicella, J.P. (2013). Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair. Nucleic Acids Res. 41, 3115-3129.
5. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
6. Hu, C.K., Coughlin, M., Field, C.M., and Mitchison, T.J. (2011). KIF4 regulates midzone length during cytokinesis. Curr. Biol. 21, 815-824.
7. Huambachano, O., Herrera, F., Rancourt, A., and Satoh, M.S. (2011). Double-stranded DNA binding domain of poly(ADP-ribose) polymerase-1 and molecular insight into the regulation of its activity. J. Biol. Chem. 286, 7149-7160.
8. Hydock, D.S., Lien, C.Y., Jensen, B.T., Parry, T.L., Schneider, C.M., and Hayward, R. (2012). Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity. Exp. Biol. Med. 237, 1483-1492.
9. Ibragimova, I., and Cairns, P. (2011). Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol. Biol. 780, 277-291.
10. Jacot, W., Thezenas, S., Senal, R., Viglianti, C., Laberenne, A.C., Lopez-Crapez, E., Bibeau, F., Bleuse, J.P., Romieu, G., and Lamy, P.J. (2013). BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer 13, 523.
11. Javle, M., and Curtin, N.J. (2011). The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105, 1114-1122.
12. Langelier, M.F., Planck, J.L., Roy, S., and Pascal, J.M. (2011). Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J. Biol. Chem. 286, 10690-10701.
13. Lee Kraus, W., and Hottiger, M.O. (2013). PARP-1 and gene regulation: progress and puzzles. Mol. Aspects Med. 34, 1109-1123.
14. Martinez-Romero, R., Canuelo, A., Siles, E., Oliver, F.J., and Martinez-Lara, E. (2012). Nitric oxide modulates hypoxiainducible factor-1 and poly(ADP-ribose) polymerase-1 cross talk in response to hypobaric hypoxia. J. Appl. Physiol. 112, 816-823.
15. Midorikawa, R., Takei, Y., and Hirokawa, N. (2006). KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity. Cell 125, 371-383.
16. Munoz-Gamez, J.A., Martin-Oliva, D., Aguilar-Quesada, R., Canuelo, A., Nunez, M.I., Valenzuela, M.T., Ruiz de Almodovar, J.M., De Murcia, G., and Oliver, F.J. (2005). PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem. J. 386, 119-125.
17. Oonk, A.M., van Rijn, C., Smits, M.M., Mulder, L., Laddach, N., Savola, S.P., Wesseling, J., Rodenhuis, S., Imholz, A.L., and Lips, E.H. (2012). Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann. Oncol. 23, 2301-2305.
18. Shrestha, S., Wilmeth, L.J., Eyer, J., and Shuster, C.B. (2012). PRC1 controls spindle polarization and recruitment of cytokinetic factors during monopolar cytokinesis. Mol. Biol. Cell 23, 1196-1207.
19. Stanisavljevic, J., Porta-de-la-Riva, M., Batlle, R., de Herreros, A.G., and Baulida, J. (2011). The p65 subunit of NF-kappaB and PARP1 assist Snail1 in activating fibronectin transcription. J. Cell Sci. 124, 4161-4171.
20. Sukowati, C.H., Rosso, N., Pascut, D., Anfuso, B., Torre, G., Francalanci, P., Croce, L.S., and Tiribelli, C. (2012). Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol. 12, 160.
21. Sun, S., Chen, Z., Li, L., Sun, D., Tian, Y., Pan, H., Bi, H., Huang, M., Zeng, S., and Jiang, H. (2012). The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. Xenobiotica 42, 1197-1205.
22. Villar, V.H., Vogler, O., Martinez-Serra, J., Ramos, R., Calabuig-Farinas, S., Gutierrez, A., Barcelo, F., Martin-Broto, J., and Alemany, R. (2012). Nilotinib counteracts P-glycoproteinmediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 7, e37735.
23. Wandke, C., Barisic, M., Sigl, R., Rauch, V., Wolf, F., Amaro, A.C., Tan, C.H., Pereira, A.J., Kutay, U., Maiato, H., et al. (2012). Human chromokinesins promote chromosome congression and spindle microtubule dynamics during mitosis. J. Cell Biol. 198, 847-863.
24. Wu, G., Zhou, L., Khidr, L., Guo, X.E., Kim, W., Lee, Y.M., Krasieva, T., and Chen, P.L. (2008). A novel role of the chromokinesin Kif4A in DNA damage response. Cell Cycle 7, 2013-2020.
25. Xu, Y., Diao, Y., Qi, S., Pan, X., Wang, Q., Xin, Y., Cao, X., Ruan, J., Zhao, Z., Luo, L., et al. (2013). Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis. Cell. Signal. 25, 1176-1185.
26. Zaremba, T., Thomas, H., Cole, M., Plummer, E.R., and Curtin, N.J. (2010). Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemother. Pharmacol. 66, 807-812.
27. Zheng, Z., Aojula, H., and Clarke, D. (2010). Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide. J. Drug Target. 18, 477-487.